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Background: Second-generation stents differ from first-generation stents due to reduced strut and polymer thickness and the overall amount 
of drug loaded onto the stent. Endeavor and Xience V trials demonstrated reduction in periprocedural creatine phosphokinase (CPK-MB) release 
when compared to Taxus. This study aimed to compare the periprocedural CPK-MB release post-PCI in all 4 drug-eluting stents (DES) available for 
marketing in the US.
Methods: We studied a cohort of 8296 consecutive patients who underwent elective unrestricted PCI with DES from 2002-2009. Patients with 
abnormal CPK-MB prior to PCI were excluded. The following stents were included: Xience V (n = 583), Endeavor (n = 282), Taxus-Express (n = 2194) 
and Cypher (n = 5237). The increase of CPK-MB post-PCI was recorded and compared.
Results: Baseline characteristics were similar, although the Xience V group had younger patients (p = 0.04) and the Endeavor group was more 
hypertensive (p<0.001) and had a history of prior MI (p = 0.009). The number of implanted stents per patient was similar among the 4 groups 
(p = 0.5). Patients who received the Xience V stent had less CPK-MB rise post-PCI when compared with the other DES groups (p = 0.03) and less 
incidence of MI post-procedure when compared to any other group (p = 0.02). (Figure)
Conclusions: Xience V is associated with the lowest periprocedural CPK-MB increase post-PCI, which leads to less MI. This may be attributed to the 
lowest thickness (combination of both strut and polymer).
